Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-cash Items (2018 - 2025)

Aytu Biopharma (AYTU) has disclosed Non-cash Items for 8 consecutive years, with $138042.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 30.98% to $138042.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $138042.0 through Dec 2025, down 30.98% year-over-year, with the annual reading at $100000.0 for FY2025, 298.91% up from the prior year.
  • Non-cash Items for Q4 2025 was $138042.0 at Aytu Biopharma, up from $103898.0 in the prior quarter.
  • The five-year high for Non-cash Items was $200000.0 in Q2 2022, with the low at $3019.0 in Q3 2023.
  • Average Non-cash Items over 5 years is $104558.5, with a median of $100000.0 recorded in 2022.
  • The sharpest move saw Non-cash Items crashed 96.98% in 2023, then surged 3212.36% in 2024.
  • Over 5 years, Non-cash Items stood at $47838.0 in 2021, then surged by 318.08% to $200000.0 in 2022, then plummeted by 89.76% to $20470.0 in 2023, then surged by 877.04% to $200000.0 in 2024, then tumbled by 30.98% to $138042.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $138042.0, $103898.0, and $100000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.